17/08/2026 Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis Argenx announced positive results from the phase 3 ALKIVIA study of efgartigimod in autoimmune myositis (Ref) Argenx announced positive topline results from the Phase 3, ALKIVIA/ NCT05523167 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. The study met its primary endpoint of mean Total Improvement

27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa